2QB0 Stock Overview
Engages in research, development, production, and sale of vision enhancement products in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Ocumetics Technology Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.18 |
| 52 Week High | CA$0.26 |
| 52 Week Low | CA$0.16 |
| Beta | -1.12 |
| 11 Month Change | 1.13% |
| 3 Month Change | 5.29% |
| 1 Year Change | -7.73% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -10.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2QB0 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -0.6% | -0.4% | -0.4% |
| 1Y | -7.7% | -7.1% | 7.1% |
Return vs Industry: 2QB0 underperformed the German Medical Equipment industry which returned -6.1% over the past year.
Return vs Market: 2QB0 underperformed the German Market which returned 7.8% over the past year.
Price Volatility
| 2QB0 volatility | |
|---|---|
| 2QB0 Average Weekly Movement | 14.9% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2QB0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2QB0's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Dean Burns | ocumetics.com |
Ocumetics Technology Corp. engages in research, development, production, and sale of vision enhancement products in Canada. The company provides intraocular lenses primarily for people over 45 years of age. The company was formerly known as Quantum Blockchain Technologies Ltd.
Ocumetics Technology Corp. Fundamentals Summary
| 2QB0 fundamental statistics | |
|---|---|
| Market cap | €26.01m |
| Earnings (TTM) | -€1.95m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-13.4x
P/E RatioIs 2QB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2QB0 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.87m |
| Earnings | -CA$2.87m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -35.4% |
How did 2QB0 perform over the long term?
See historical performance and comparison